Wolfe Research initiated coverage of Intellia Therapeutics with a Peer Perform rating. Reimbursement hurdles for competitors and lower safety risks compared to ex vivo methods may drive increased appreciation for Intellia’s in vivo approach but not in the near-term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTLA:
- Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
- Cathie Wood’s ARK Investment bought 131K shares of Intellia Therapeutics today
- Intellia Therapeutics Reveals Positive Phase 1 Results
- Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
- Intellia Therapeutics announces publication of NTLA-2002 data in NEJM
